We greatly appreciated the comments and questions raised in the initial review of our manuscript. We address the points from each reviewer below. Reviewer comments are in black and our responses in blue. Changes to the manuscript are highlighted in yellow.
We agree with the reviewer that this is a surprising result! Nevertheless, it was a robust and reproducible observation. We hypothesize that although both ICOS KO and ICOS YF Tregs lack the ability to activate PI3K, ICOS YF Tregs presumably have other intact signaling pathways downstream of ICOS. We hypothesize that these pathways (which are abolished in ICOS KO Tregs) are what is impacting the ability of ICOS YF Tregs to maintain Foxp3 and CD25 in the context of the inflamed brain. For this reason, we expect these particular results to be of interest to researchers that study ICOS signaling.
Other concerns: All effector T cells in the brain during chronic infection express some level of Bcl-2, therefore the percent positive for all genotypes is 100%. However, the levels of Bcl-2 expression on a per-cell basis changes in the CD4+ effector T cell compartment in ICOS KO and ICOS YF mice. Representative histograms of Bcl-2 expression are now included in Figure 1G for clarity. Fig. 2A -D. Show also absolute numbers of FoxP3+ cells in addition to percentages. Since the FoxP3-cell number is expanded in the mutant mice, it is possible that there is no difference on Treg number.
We agree with the reviewer that absolute number and percentages are relevant regarding Tregs. The requested data are now included in Figure 2E and described in the text in lines 295-6. Fig. 3 . The dramatic effect of ICOS on antibody responses is striking, but no direct evidence is provided that this results in increased susceptibility show in the figure. The authors could determine whether anti-serum infusion corrected the decrease in resistance.
We agree with the reviewer that we have not directly implicated antibody defects in the control of cyst burden. For this manuscript, we are reporting the similarities and differences between ICOS KO and ICOS YF mice during infection with T. gondii. We do not feel that we overstated our results and contend that it is merely our hypothesis that antibody defects are resulting in increased cyst burdens.
Reviewer #2: In this report, Taije and colleagues investigated the role of ICOS signalling via PI3K during Toxoplasma gondii infection. This is an extension to their original studies, recently published in the Journal of immunology (O'Brien CA et al., 2019). In the present study, their findings suggest that this signalling pathway may be important in supporting regulatory T cell homeostasis. Their studies are technically sound and may be important for the readership at PLoS One. Some minor changes to the current text and figures may improve the quality of this manuscript for publication purposes. We agree that the flow plots add more information for the reader. These data are now included in Figure 1C , Figure 1E , and Figure 1G Axis labels have been added to these plots for increased clarity.
3. Axis labels should be added to FACS plots presented in figure 4A and 4C.
Axis labels have been added to these plots for increased clarity.
Text:
The authors should consider removing figure legends from the main text of the manuscript. These should go to a separate section.
The figure legends have now been embedded in the Results section as per PLoS One guidelines.
Minor scientific comment
Did the authors measure inflammatory cytokines in the brains of WT and ICOSKO/YF mice? In addition, did the authors examine the phenotype of the effector cells recruited to the brains during infection. If so, this data may be a good addition to the manuscript.
We agree that an analysis of the effector T cells is also of great interest. Because we observed changes in CD25 and Bcl-2 expression in our 2019 publication, we examined the number of effector T cells in the brain along with their expression of CD25 and Bcl-2. We have not examined cytokine production, but expect results to be similar to anti-ICOSL treatment, where IFN-g production does not change on a per cell basis, but there is an increase in effector cells in the brain leading to an overall increase in cytokine production.
Reviewer #3: The authors present a study to understand the role of ICOS in response to chronic T. gondii infection. Two mutant mouse models are used, one full knock-out and one with a single amino acid substitution (Y to F) to prevent the recruitment and activation of PI3K. Results found that the overall Tcell numbers in the brain is increased in both mutant mouse lines after T. gondii infection, although the number of Treg cells were reduced. Both mutations caused a lack of an antibody response to T. gondii, which in turn, resulted in a higher brain cyst burden. The major differences between the KO and YF mutants were the reduction of Foxp3 expression on Treg cells and the number of CD25+ Treg cells, both of which were reduced in the YF compared to the full KO.
Major Comments:
1. Clarify why it's stated (lines 294-295) that Foxp3 defects are only in Treg cells of the brain, when they show they are reduced in brain and spleen (Fig 2E and  H) .
We thank the reviewer for pointing out the lack of clarity in the text regarding these results. The text describing these results has now been changed to describe in more detail the Treg defects in the brain and spleen in lines 316-329.
2. The authors state multiple times in the results (e.g. Lines 256 and 291) that CD25 expression levels are changing, however, that data is not shown. Data in Fig 2 shows the percentage of CD25+ cells but not the intensity of their expression. The data and/or text needs to be changed to match one another.
The data showing the MFI of CD25+ Tregs in both the brain and spleen are now included in Figure 2H and Figure 2L , respectively. These results are described in the text in lines 316-325.
3. To go along with the cyst data (Fig 3) , authors should show if either of the mouse mutations have an effect on the survival or health of the mice up to chronic infection.
Though both ICOS KO and ICOS YF mice survived the acute stage of infection and the early chronic phase in our hands, we did observe increased sickness in these mice compared to WT (increased ruffled fur, less activity), suggesting that the inability to control parasite burden in the brain might lead to survival defects in later chronic stages of infection.
4.
It's interesting that lack of PI3K signaling reduced Foxp3 expression and CD25 expressing cells but the KO did not, since this mutation also lacks the PI3K signaling. Although this starts to get explained in the discussion, more clarification as to how lacking both PI3K and the other potential cytoplasmic signaling can revert the phenotype back to wild type, since this is all on one protein can be a little counterintuitive.
It has been suggested in the literature that Tregs are very sensitive to PI3K activation levels, where too much or too little PI3K activation can negatively impact their survival and function (Abu-Eid, et al., 2014 & Sauer, et al. 2008 . It is possible that the additional signaling pathways downstream of ICOS besides PI3K (which are intact in ICOS YF Tregs) serve as a pathway to negatively regulate activation of PI3K, as has been shown in Tfh cells (Pedros, et al. 2016 ). If this is true in Tregs, WT Tregs might recruit and activate PI3K downstream of ICOS, but also activate these negative regulatory pathways that prevent "too much" PI3K activation, leading to balanced PI3K activation in the Treg. In ICOS YF Tregs, the inability to activate PI3K is lost, so only these potential negative pathways are activated downstream of ICOS. If only these pathways are activated downstream of ICOS in ICOS YF Tregs, they might negatively impact PI3K too much, leading to too little PI3K activation, with has also been shown to decrease Treg Foxp3 expression. In ICOS KO Tregs, both the positive PI3K signal and the negative signal are lost, meaning the "balance" is maintained enough (possibly through other PI3K activating signals that can compensate for the loss of ICOS such as TCR/MHC, CD28, or IL-2) for ICOS KO Tregs to maintain Foxp3 and CD25 expression in the inflamed brain. Additional comments regarding this hypothesis have been added to the discussion in lines 464-472.
